Affinity DataKi: 4.80nMAssay Description:Agonist activity at dopamine D5 receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: 6.80nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 8.5nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 8.90nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 8.90nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 21.6nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 38nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 56nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 99nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 121nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 243nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 244nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 254nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 376nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 563nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 1.68E+3nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 2.24E+3nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 2.35E+3nMAssay Description:Displacement of [3H]-SCH23390 from human dopamine D1 receptor expressed in LTK cell membranes after 30 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:Agonist activity at dopamine D2 receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 0.0140nMAssay Description:Inhibition of BACE1 in human H4 cells transfected with wild type APP assessed as reduction in soluble portion of APPbeta level in cells incubated for...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0330nMAssay Description:Inhibition of BACE1 in human H4 cells transfected with wild type APP assessed as reduction in soluble portion of APPbeta level in cells incubated for...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0340nMAssay Description:Inhibition of BACE1 in human H4 cells transfected with wild type APP assessed as reduction in soluble portion of APPbeta level in cells incubated for...More data for this Ligand-Target Pair
Affinity DataIC50: 0.110nMAssay Description:Inhibition of BACE1 in human H4 cells transfected with wild type APP assessed as reduction in soluble portion of APPbeta level in cells incubated for...More data for this Ligand-Target Pair
Affinity DataIC50: <0.300nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
Affinity DataIC50: <0.310nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
Affinity DataIC50: 0.380nMAssay Description:Inhibition of human BACE2More data for this Ligand-Target Pair
Affinity DataIC50: <0.410nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B [122-736](Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: <0.450nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
Affinity DataIC50: <0.488nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
TargetIsoform 4 of cAMP-specific 3',5'-cyclic phosphodiesterase 4A (RD1)(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: <0.488nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
Affinity DataIC50: <0.488nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B [122-736](Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: <0.540nMAssay Description:Inhibition of BACE1 in human H4 cells transfected with wild type APP assessed as reduction in soluble portion of APPbeta level in cells incubated for...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B [122-736](Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.600nMAssay Description:Inhibition of human BACE1More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B [122-736](Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.640nMAssay Description:Inhibition of BACE1 in human H4 cells transfected with wild type APP assessed as reduction in soluble portion of APPbeta level in cells incubated for...More data for this Ligand-Target Pair
Affinity DataIC50: <0.669nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
TargetIsoform 4 of cAMP-specific 3',5'-cyclic phosphodiesterase 4A (RD1)(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: <0.669nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
Affinity DataIC50: <0.669nMAssay Description:Human PDE4A3 coding sequence (amino acids 2 to 825 from the sequence with accession number NP_001104779) was cloned into the baculovirus expression v...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B [122-736](Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: <0.670nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B [122-736](Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.700nMAssay Description:Beta-secretase (BACE) is one of the enzymes involved in the generation of the amyloid beta peptide found in the amyloid plaques of Alzheimer's Di...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B [122-736](Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B [122-736](Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B [122-736](Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.900nMAssay Description:Inhibition of human BACE1More data for this Ligand-Target Pair